Hypertension in idiopathic pulmonary fibrosis: evidence of immune and genetic links from clinical and genomic analyses

特发性肺纤维化合并高血压:临床和基因组分析表明存在免疫和遗传联系

阅读:3

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease (ILD) with high mortality and a high prevalence of comorbidities. Hypertension is among the most common extrapulmonary complications, but the underlying mechanisms linking IPF and hypertension remain poorly understood. This study aimed to explore the potential causal relationship and shared immune-genetic mechanisms between IPF and hypertension. METHODS: A real-world cohort of 110 IPF patients from Peking Union Medical College Hospital (PUMCH) was enrolled. Clinical comorbidity profiles were analyzed, and whole-exome sequencing (WES) was performed on peripheral blood samples. Two-sample Mendelian randomization (MR) analysis was conducted using PUMCH data and external GWAS summary statistics to assess the causal effect of IPF genetic susceptibility on hypertension. Functional enrichment, protein-protein interaction (PPI) networks, and immune pathway analysis were performed, followed by multi-tiered validation through qPCR, Western blotting, and immunohistochemistry. RESULTS: Hypertension was observed in 61.8% of IPF patients and was independently associated with poor survival. Two-sample MR analyses based on both internal WES and external GWAS data supported a causal effect of IPF genetic susceptibility on hypertension. Enrichment analyses revealed involvement in antigen presentation and immune regulation. CD74, HLA-DPA1, and HLA-DRA were consistently downregulated in comorbid IPF and hypertension across GEO datasets and experimental validation, suggesting impaired antigen presentation as a key mechanistic link. CONCLUSION: This study provides genetic and immunological evidence supporting a causal relationship between IPF and hypertension. Dysregulated antigen presentation may serve as a common pathogenic pathway, offering potential targets for precision comorbidity management in IPF patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。